A Phase 3 Randomized Double-blind Multicenter Study of TSR-042 plus Carboplatin-Paclitaxel versus Placebo plus Carboplatin-Paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Endometrial Cancer
  • Age: Between 18 - 100 Years
  • Gender: Female
  • Other Inclusion Criteria:
    1) Patient has histologically or cytologically proven endometrial cancer with recurrent or advanced disease. 2) Patient must have primary Stage III or Stage IV disease or first recurrent endometrial cancer with a low potential for cure by radiation therapy or surgery alone or in combination.

You may not be eligible for this study if the following are true:

  • 1) Patient has received neo-adjuvant/adjuvant systemic chemotherapy for primary Stage III or IV disease and: has not had a recurrence or progression of disease prior to entering the study OR has had a recurrence or progression of disease within 6 months of completing chemotherapy treatment prior to entering the study 2) Patient has had > 1 recurrence of endometrial cancer. 3) Patient has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent (immunotherapy drugs).

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.